<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00925288</url>
  </required_header>
  <id_info>
    <org_study_id>Merck IISP 35706</org_study_id>
    <secondary_id>IRB00001625</secondary_id>
    <nct_id>NCT00925288</nct_id>
  </id_info>
  <brief_title>Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers</brief_title>
  <acronym>Girasol</acronym>
  <official_title>Acceptability and Feasibility of a Modified HPV Vaccine Schedule in Brothel Based Female Sex Workers in Peru</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>NGO Via Libre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Peruana Cayetano Heredia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to determine the acceptance and potential for the
      effective use of HPV vaccine in the standard and a modified schedule in female sex workers.
      Secondary objectives include ascertaining the prevalence of HPV types among female sex
      workers by age and sexual experience.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FSWs are at higher risk of HPV infection and presumably cervical cancer, and the recently
      available vaccine has been shown to protect against persistent infection from these types. If
      this study gives evidence showing the vaccine is acceptable in preventing cervical HPV
      infection by types 16 and 18 in this population, then the burden of cervical cancer and
      cancer precursors could be drastically decreased through widespread vaccination of this
      target group. Vaccination at the point of entry of brothel based sex work may become a
      requirement to lower the burden of cervical cancer among FSWs and also among all other sex
      partners of clients of FSWs. A modified schedule may prove beneficial for FSWs in Peru to
      complete the vaccine regimen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody Response to HPV Vaccine for HPV 6,11,16,18.</measure>
    <time_frame>Month 7</time_frame>
    <description>We measured anitbody response to HPV vaccine for HPV subtypes 6,11,16, and 18. This was compared by study arm, namely the regular and modified vaccination schedules.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Female Sex Workers Who Complete the Three Dose (0, 2, 6 Month) HPV Schedule in a Timely Manner Compared to the Modified (0, 3, 6 Month) Schedule.</measure>
    <time_frame>6 months</time_frame>
    <description>Completion of 3 doses of HPV4 vaccine was measured at 6 months for women receiving the vaccine in 0,2,6 month regimen or the modified 0,3,6 month regimen. Completion was measured as receiving dose 3 of the vaccine during the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Infection With HPV Subtypes (6,11,16,18) Among Female Sex Workers</measure>
    <time_frame>Baseline</time_frame>
    <description>Type specific prevalence of HPV6,11,16,18 among study participants, calculated using Linear Array testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify Barriers to Acceptance of HPV Vaccine Among Female Sex Workers</measure>
    <time_frame>Month 0</time_frame>
    <description>Listed doubts about the HPV vaccine. Participants were asked if they had any doubts about the vaccine prior to learning about it from the health professional. Herein we present the total number of participants who reported doubts by study arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Human Papillomavirus Infection</condition>
  <arm_group>
    <arm_group_label>Regular schedule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Duration: Gardasil HPV vaccine administered intramuscularly at 0,2,6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duration: Gardasil HPV vaccine administered intramuscularly at 0,3,6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil</intervention_name>
    <description>Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses</description>
    <arm_group_label>Regular schedule</arm_group_label>
    <arm_group_label>Modified Schedule</arm_group_label>
    <other_name>Human Papillomavirus Quadrivalent Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the age of 18 and 26 years

          -  Registered female sex worker living in Lima

          -  Healthy with no known immune deficiency

          -  Willing to participate in a study of HPV vaccine including a Pap smear, three
             pregnancy tests, blood draws, and three vaccine administrations over 7 months

          -  Willing to provide informed consent

        Exclusion Criteria:

          -  Currently pregnant or planning to get pregnant in the next six months

          -  Known immune deficiency disorder

          -  Current receipt of immunosuppressive drugs

          -  Allergy to yeast or known contraindication to HPV vaccine

          -  Women who have had their cervix removed

          -  Previous HPV vaccination

          -  Current fever over 100 degrees Fahrenheit
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal Halsey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NGO Via Libre</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <reference>
    <citation>de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007 Jul;7(7):453-9. Review.</citation>
    <PMID>17597569</PMID>
  </reference>
  <reference>
    <citation>Mak R, Van Renterghem L, Cuvelier C. Cervical smears and human papillomavirus typing in sex workers. Sex Transm Infect. 2004 Apr;80(2):118-20.</citation>
    <PMID>15054172</PMID>
  </reference>
  <reference>
    <citation>Juárez-Figueroa LA, Wheeler CM, Uribe-Salas FJ, Conde-Glez CJ, Zampilpa-Mejía LG, García-Cisneros S, Hernández-Avila M. Human papillomavirus: a highly prevalent sexually transmitted disease agent among female sex workers from Mexico City. Sex Transm Dis. 2001 Mar;28(3):125-30.</citation>
    <PMID>11289192</PMID>
  </reference>
  <reference>
    <citation>Ford K, Reed BD, Wirawan DN, Muliawan P, Sutarga M, Gregoire L. The Bali STD/AIDS study: human papillomavirus infection among female sex workers. Int J STD AIDS. 2003 Oct;14(10):681-7.</citation>
    <PMID>14596772</PMID>
  </reference>
  <reference>
    <citation>del Amo J, González C, Losana J, Clavo P, Muñoz L, Ballesteros J, García-Saiz A, Belza MJ, Ortiz M, Menéndez B, del Romero J, Bolumar F. Influence of age and geographical origin in the prevalence of high risk human papillomavirus in migrant female sex workers in Spain. Sex Transm Infect. 2005 Feb;81(1):79-84.</citation>
    <PMID>15681729</PMID>
  </reference>
  <reference>
    <citation>Cañadas MP, Bosch FX, Junquera ML, Ejarque M, Font R, Ordoñez E, de Sanjosé S. Concordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk population. J Clin Microbiol. 2004 Mar;42(3):1330-2.</citation>
    <PMID>15004111</PMID>
  </reference>
  <reference>
    <citation>Kjaer SK, Svare EI, Worm AM, Walboomers JM, Meijer CJ, van den Brule AJ. Human papillomavirus infection in Danish female sex workers. Decreasing prevalence with age despite continuously high sexual activity. Sex Transm Dis. 2000 Sep;27(8):438-45.</citation>
    <PMID>10987448</PMID>
  </reference>
  <reference>
    <citation>Tideman RL, Thompson C, Rose B, Gilmour S, Marks C, van Beek I, Berry G, O'Connor C, Mindel A. Cervical human papillomavirus infections in commercial sex workers-risk factors and behaviours. Int J STD AIDS. 2003 Dec;14(12):840-7.</citation>
    <PMID>14678594</PMID>
  </reference>
  <reference>
    <citation>Anhang R, Goodman A, Goldie SJ. HPV communication: review of existing research and recommendations for patient education. CA Cancer J Clin. 2004 Sep-Oct;54(5):248-59. Review.</citation>
    <PMID>15371283</PMID>
  </reference>
  <reference>
    <citation>Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer. 2006 Oct;6(10):753-63. Review.</citation>
    <PMID>16990853</PMID>
  </reference>
  <reference>
    <citation>Burchell AN, Winer RL, de Sanjosé S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006 Aug 31;24 Suppl 3:S3/52-61. Epub 2006 Jun 2. Review.</citation>
    <PMID>16950018</PMID>
  </reference>
  <reference>
    <citation>Stanley M. Immune responses to human papillomavirus. Vaccine. 2006 Mar 30;24 Suppl 1:S16-22. Review.</citation>
    <PMID>16219398</PMID>
  </reference>
  <reference>
    <citation>Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 2006 Aug 31;24 Suppl 3:S3/42-51. Epub 2006 Jun 23. Review.</citation>
    <PMID>16950017</PMID>
  </reference>
  <reference>
    <citation>Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999 Feb 3;91(3):252-8.</citation>
    <PMID>10037103</PMID>
  </reference>
  <reference>
    <citation>Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25. Review.</citation>
    <PMID>16949997</PMID>
  </reference>
  <reference>
    <citation>Santos C, Muñoz N, Klug S, Almonte M, Guerrero I, Alvarez M, Velarde C, Galdos O, Castillo M, Walboomers J, Meijer C, Caceres E. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer. 2001 Sep 28;85(7):966-71.</citation>
    <PMID>11592767</PMID>
  </reference>
  <reference>
    <citation>Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S; IARC HPV Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005 Sep 17-23;366(9490):991-8.</citation>
    <PMID>16168781</PMID>
  </reference>
  <reference>
    <citation>Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, Meijer CJ. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer. 2000 Jul 15;87(2):221-7.</citation>
    <PMID>10861478</PMID>
  </reference>
  <reference>
    <citation>Melkert PW, Hopman E, van den Brule AJ, Risse EK, van Diest PJ, Bleker OP, Helmerhorst T, Schipper ME, Meijer CJ, Walboomers JM. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer. 1993 Apr 1;53(6):919-23.</citation>
    <PMID>8386137</PMID>
  </reference>
  <reference>
    <citation>Kitchener HC, Castle PE, Cox JT. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine. 2006 Aug 31;24 Suppl 3:S3/63-70. Review.</citation>
    <PMID>16950019</PMID>
  </reference>
  <reference>
    <citation>Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh Gv, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006 Dec 4;95(11):1459-66. Epub 2006 Nov 21.</citation>
    <PMID>17117182</PMID>
  </reference>
  <reference>
    <citation>FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10;356(19):1915-27.</citation>
    <PMID>17494925</PMID>
  </reference>
  <reference>
    <citation>Halsey NA, Moulton LH, O'Donovan JC, Walcher JR, Thoms ML, Margolis HS, Krause DS. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics. 1999 Jun;103(6 Pt 1):1243-7.</citation>
    <PMID>10353936</PMID>
  </reference>
  <reference>
    <citation>Núñez JT, Delgado M, Girón H, Pino G. Prostitution and other cofactors in preinvasive and invasive lesions of the cervix. Aust N Z J Obstet Gynaecol. 2004 Jun;44(3):239-43.</citation>
    <PMID>15191449</PMID>
  </reference>
  <reference>
    <citation>Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, Koutsky LA. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006 Jun 22;354(25):2645-54.</citation>
    <PMID>16790697</PMID>
  </reference>
  <reference>
    <citation>Ohshige K, Morio S, Mizushima S, Kitamura K, Tajima K, Suyama A, Usuku S, Tia P, Hor LB, Heng S, Saphonn V, Tochikubo O, Soda K. Behavioural and serological human immunodeficiency virus risk factors among female commercial sex workers in Cambodia. Int J Epidemiol. 2000 Apr;29(2):344-54.</citation>
    <PMID>10817135</PMID>
  </reference>
  <reference>
    <citation>Miller GA, Mendoza W, Krone MR, Meza R, Caceres CF, Coates TJ, Klausner JD. Clients of female sex workers in Lima, Peru: a bridge population for sexually transmitted disease/HIV transmission? Sex Transm Dis. 2004 Jun;31(6):337-42.</citation>
    <PMID>15167641</PMID>
  </reference>
  <reference>
    <citation>Trujillo L, Muñoz D, Gotuzzo E, Yi A, Watts DM. Sexual practices and prevalence of HIV, HTLV-I/II, and Treponema pallidum among clandestine female sex workers in Lima, Peru. Sex Transm Dis. 1999 Feb;26(2):115-8.</citation>
    <PMID>10029987</PMID>
  </reference>
  <reference>
    <citation>Paris M, Gotuzzo E, Goyzueta G, Aramburu J, Caceres CF, Castellano T, Jordan NN, Vermund SH, Hook EW 3rd. Prevalence of gonococcal and chlamydial infections in commercial sex workers in a Peruvian Amazon city. Sex Transm Dis. 1999 Feb;26(2):103-7.</citation>
    <PMID>10029985</PMID>
  </reference>
  <reference>
    <citation>García PJ, Chavez S, Feringa B, Chiappe M, Li W, Jansen KU, Cárcamo C, Holmes KK. Reproductive tract infections in rural women from the highlands, jungle, and coastal regions of Peru. Bull World Health Organ. 2004 Jul;82(7):483-92.</citation>
    <PMID>15508193</PMID>
  </reference>
  <reference>
    <citation>Sánchez J, Gotuzzo E, Escamilla J, Carrillo C, Phillips IA, Barrios C, Stamm WE, Ashley RL, Kreiss JK, Holmes KK. Gender differences in sexual practices and sexually transmitted infections among adults in Lima, Peru. Am J Public Health. 1996 Aug;86(8):1098-107.</citation>
    <PMID>8712268</PMID>
  </reference>
  <reference>
    <citation>Sánchez J, Campos PE, Courtois B, Gutierrez L, Carrillo C, Alarcon J, Gotuzzo E, Hughes J, Watts D, Hillier SL, Buchanan K, Holmes KK. Prevention of sexually transmitted diseases (STDs) in female sex workers: prospective evaluation of condom promotion and strengthened STD services. Sex Transm Dis. 2003 Apr;30(4):273-9.</citation>
    <PMID>12671544</PMID>
  </reference>
  <reference>
    <citation>Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med. 2006 May;3(5):e138. Epub 2006 Apr 4.</citation>
    <PMID>16573364</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2009</study_first_posted>
  <results_first_submitted>July 3, 2012</results_first_submitted>
  <results_first_submitted_qc>September 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 11, 2012</results_first_posted>
  <last_update_submitted>September 10, 2012</last_update_submitted>
  <last_update_submitted_qc>September 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins Bloomberg School of Public Health</investigator_affiliation>
    <investigator_full_name>Neal Halsey</investigator_full_name>
    <investigator_title>Professor of International Health</investigator_title>
  </responsible_party>
  <keyword>Female sex worker</keyword>
  <keyword>Peru</keyword>
  <keyword>Cervical infection</keyword>
  <keyword>Cervical abnormality</keyword>
  <keyword>Serum antibody</keyword>
  <keyword>Vaccine acceptance</keyword>
  <keyword>Alternative schedule</keyword>
  <keyword>Viral infections</keyword>
  <keyword>Human papillomavirus vaccine</keyword>
  <keyword>Human papillomavirus (HPV)</keyword>
  <keyword>non inferiority</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>FSWs 18-26 years of age were recruited in person between August 28, 2009 and March 3, 2010 from 49 different sex locales in Lima, Peru by trained medical staff and 8 health promoters. If they fulfilled inclusion criteria, women were asked to report to the study clinic for completion of surveys, vaccination, Pap smears, and counseling.</recruitment_details>
      <pre_assignment_details>Some eligible participants provided a false phone number, did not show up for their study appointment, refused to use birth control when receiving vaccine doses, and reported not having time to participate in the study. After the survey and Pap smear, vaccination was the final step in study enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Regular Schedule</title>
          <description>Duration: 0,2,6 months each dose Dose form: standard injectable HPV4 vaccine Groups: FSWs 18-26 years of age</description>
        </group>
        <group group_id="P2">
          <title>Modified Schedule</title>
          <description>Duration: 0,3,6 months each dose Dose form: standard injectable HPV4 vaccine Groups: FSWs 18-26 years of age</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Regular Schedule</title>
          <description>Duration: 0,2,6 months</description>
        </group>
        <group group_id="B2">
          <title>Modified Schedule</title>
          <description>Duration: 0,3,6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.86" spread="2.33"/>
                    <measurement group_id="B2" value="22.97" spread="2.17"/>
                    <measurement group_id="B3" value="22.92" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to HPV Vaccine for HPV 6,11,16,18.</title>
        <description>We measured anitbody response to HPV vaccine for HPV subtypes 6,11,16, and 18. This was compared by study arm, namely the regular and modified vaccination schedules.</description>
        <time_frame>Month 7</time_frame>
        <population>All participants who returned for the final blood draw considered in the final antibody analysis. The analysis applies to antibody levels after vaccination for HPV6, HPV11, HPV16, and HPV18. This is done for each study arm, namely the regular schedule and the modified schedule.</population>
        <group_list>
          <group group_id="O1">
            <title>Regular Schedule</title>
            <description>Duration: 0,2,6 months</description>
          </group>
          <group group_id="O2">
            <title>Modified Schedule</title>
            <description>Duration: 0,3,6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to HPV Vaccine for HPV 6,11,16,18.</title>
          <description>We measured anitbody response to HPV vaccine for HPV subtypes 6,11,16, and 18. This was compared by study arm, namely the regular and modified vaccination schedules.</description>
          <population>All participants who returned for the final blood draw considered in the final antibody analysis. The analysis applies to antibody levels after vaccination for HPV6, HPV11, HPV16, and HPV18. This is done for each study arm, namely the regular schedule and the modified schedule.</population>
          <units>Milli Merck Units</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1086.49" lower_limit="854.16" upper_limit="1382.0"/>
                    <measurement group_id="O2" value="1054.13" lower_limit="808.42" upper_limit="1374.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="745.06" lower_limit="588.82" upper_limit="942.76"/>
                    <measurement group_id="O2" value="776.84" lower_limit="644.03" upper_limit="936.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3235.89" lower_limit="2661.93" upper_limit="3933.61"/>
                    <measurement group_id="O2" value="2704.62" lower_limit="2301.71" upper_limit="3178.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="603.39" lower_limit="487.81" upper_limit="746.35"/>
                    <measurement group_id="O2" value="531.66" lower_limit="441.68" upper_limit="639.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that both schedules will provide an equivalent antibody response.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Since the standard schedule is at (0, 2, 6 months), and the modified schedule at (0, 3, 6 months), we will consider this a non-inferiority study. With 80% power, type 1 error of 0.05, standard deviations of 0.6, and an equivalence margin of 0.3, 64 women are needed per group to detect non-inferiority. Having 100 women in each study arm will yield over 94% power to detect non-inferiority of the modified schedule.</non_inferiority_desc>
            <p_value>&gt;0.20</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Female Sex Workers Who Complete the Three Dose (0, 2, 6 Month) HPV Schedule in a Timely Manner Compared to the Modified (0, 3, 6 Month) Schedule.</title>
        <description>Completion of 3 doses of HPV4 vaccine was measured at 6 months for women receiving the vaccine in 0,2,6 month regimen or the modified 0,3,6 month regimen. Completion was measured as receiving dose 3 of the vaccine during the study.</description>
        <time_frame>6 months</time_frame>
        <population>All participants were included</population>
        <group_list>
          <group group_id="O1">
            <title>Regular Schedule</title>
            <description>Duration: 0,2,6 months</description>
          </group>
          <group group_id="O2">
            <title>Modified Schedule</title>
            <description>Duration: 0,3,6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Female Sex Workers Who Complete the Three Dose (0, 2, 6 Month) HPV Schedule in a Timely Manner Compared to the Modified (0, 3, 6 Month) Schedule.</title>
          <description>Completion of 3 doses of HPV4 vaccine was measured at 6 months for women receiving the vaccine in 0,2,6 month regimen or the modified 0,3,6 month regimen. Completion was measured as receiving dose 3 of the vaccine during the study.</description>
          <population>All participants were included</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Completion rates compared in the 2 study arms</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Infection With HPV Subtypes (6,11,16,18) Among Female Sex Workers</title>
        <description>Type specific prevalence of HPV6,11,16,18 among study participants, calculated using Linear Array testing.</description>
        <time_frame>Baseline</time_frame>
        <population>All participants were included in the analysis for baseline HPV DNA prevalence</population>
        <group_list>
          <group group_id="O1">
            <title>Regular Schedule</title>
            <description>Duration: 0,2,6 months</description>
          </group>
          <group group_id="O2">
            <title>Modified Schedule</title>
            <description>Duration: 0,3,6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Infection With HPV Subtypes (6,11,16,18) Among Female Sex Workers</title>
          <description>Type specific prevalence of HPV6,11,16,18 among study participants, calculated using Linear Array testing.</description>
          <population>All participants were included in the analysis for baseline HPV DNA prevalence</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison of differences in HPV DNA prevalence by study arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Identify Barriers to Acceptance of HPV Vaccine Among Female Sex Workers</title>
        <description>Listed doubts about the HPV vaccine. Participants were asked if they had any doubts about the vaccine prior to learning about it from the health professional. Herein we present the total number of participants who reported doubts by study arm.</description>
        <time_frame>Month 0</time_frame>
        <population>All participants who listed doubts about the vaccine are counted here.</population>
        <group_list>
          <group group_id="O1">
            <title>Regular Schedule</title>
            <description>Participants in 0,2,6 month study arm</description>
          </group>
          <group group_id="O2">
            <title>Modified Schedule</title>
            <description>Participants in 0,3,6 month study arm</description>
          </group>
        </group_list>
        <measure>
          <title>Identify Barriers to Acceptance of HPV Vaccine Among Female Sex Workers</title>
          <description>Listed doubts about the HPV vaccine. Participants were asked if they had any doubts about the vaccine prior to learning about it from the health professional. Herein we present the total number of participants who reported doubts by study arm.</description>
          <population>All participants who listed doubts about the vaccine are counted here.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Regular Schedule</title>
          <description>Duration: 0,2,6 months</description>
        </group>
        <group group_id="E2">
          <title>Modified Schedule</title>
          <description>Duration: 0,3,6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small time difference between study arms (0,2,6 and 0,3,6 months); We cannot distinguish between antibodies resulting from vaccination and antibodies resulting from natural HPV infection;</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Brandon Brown</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>949-266-4401</phone>
      <email>bbrown@jhsph.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

